A Single Center, Prospective Study Evaluating the Anti-fibrotic Effect of Combination Therapy of Peginterferon Alpha-2a Plus Ribavirin in Patients With Chronic Hepatitis C, Based on Histologic Changes and Noninvasive Fibrosis Assessments
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 18 Oct 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 13 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 13 Oct 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.
- 01 Dec 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.